Docetaxel in ovarian cancer

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 15, 2005, Pages 2719-2726

  Escobar, Pedro F ^a   Rose, Peter G ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Docetaxel; Ovarian cancer; Paclitaxel resistance

Indexed keywords

ABC TRANSPORTER A1; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TUBULIN; ASPARTATE AMINOTRANSFERASE; BETA TUBULIN; BILIRUBIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE; DOCETAXEL; GABAPENTIN; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NARCOTIC AGENT; ONCOPROTEIN; PACLITAXEL; PACLITAXEL DERIVATIVE; PROTEIN BCL 2; STEROID; TOPOTECAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL TRIAL; CYTOTOXICITY; DEPOLYMERIZATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIPHORA; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; IN VITRO STUDY; LIVER METABOLISM; MAXIMUM PERMISSIBLE DOSE; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TARGET CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; TAXOIDS;

EID: 29244487074     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.15.2719     Document Type: Review

References (51)

1. BISSERY M-C, NOHYNEK G, SANDERINK G-J, LAVELLE F: Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs (1995) 6:339-355.
2. RINGEL I, HORWITZ SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Nat. Cancer Inst. (1991) 83:288-291.
3. NOGALES E, WOLFF SG, DOWNING KH: Structure of the αβ tubulin dimmer by electron crystallography. Nature (1998) 391:199-202.
4. HALDAL S, BASU A, CROCE CM: Bcl2 is the guardian of microtubule integrity. Cancer Res. (1997) 57:229-233.
5. KELLAND LR, ABELG: Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. (1992) 30(6):444-450.
6. BOLLAG DM, MCQUEENEY PA, ZHU J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. (1995) 55:2325-2333.
7. UYAR D, TAKIGAWA N, MEKHAIL T et al.: Apoptotic pathways of epothilone BMS 310705. Gynecol. Oncol. (2003) 91:173-178.
8. HORWITZ SB: Mechanism of action of taxol. Trends Pharmacol. Sci. (1992) 13:134-136.
9. KEATES RAB, SARANGI F, LING V: Structural and functional alterations in microtubule protein from Chinese hamster ovary cell mutants. Proc. Nat. Acad. Sci. USA (1981) 78:5638-5642.
10. DUMONTET C, DURAN GE, STEGER KA, BEKETIC-ORESKOVIC L, SIKIC BI: Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. (1996) 56:1091-1097.
11. KRUH GD, BELINSKY MG: The MRP family of drug efflux pumps. Oncogene (2003) 22:7537-7552.
12. HOPPER-BORGE E, CHEN ZS, SHCHAVELEVA I, BELINSKY MG, KRUH GD: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. (2004) 64:4927-4930.
13. THIGPEN JT, BLESSING JA, BALL H et al.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecological Oncology Group study. J. Clin. Oncol. (1994) 12:1748-1753.
14. MCGUIRE WP, BLESSING JA, BOOKMAN MA et al.: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecological Oncology Group study. J. Clin. Oncol. (2000) 18:1062-1067.
15. MARKMAN M, KENNEDY A, WEBSTER K, KULP B, PETERSON G, BELINSON J: Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J. Cancer Res. Clin. Oncol. (1998) 124(6):326-328.
16. AAPRO MS: Docetaxel (Taxotere): a highly active taxoid with manageable toxicity. Semin. Oncol. (1995) 22(2 Suppl. 4):1-2.
17. PICCART MJ, GORE M, TEN BOKKEL HUININK W et al.: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. Nat. Cancer Inst. (1995) 87:676-681.
18. FRANCIS P, SCHNEIDER J, HANN L et al.: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. Clin. Oncol. (1994) 12:2301-2308.
19. KAVANAGH JJ, KUDELKA AP, DE LEON CG et al.: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. (1996) 2:837-842.
20. KAYE SB, PICCART M, AAPRO M, FRANCIS P, KAVANAGH J: Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur. J. Cancer (1997) 33:2167-2170.
21. FUJIWARA K, KOHNO I, TANAKA K et al.: Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group. Anticancer Res. (1999) 19:639-644.
22. NIWA Y, NAKANISHI T, KUZUYA K et al.: Salvage treatment with docetaxel for recurrent epithelial ovarian cancer Int. J. Clin. Oncol. (2003) 8:343-347.
23. KATSUMATA N, TSUNEMATSU R, TANAKA K et al.: A Phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann. Oncol. (2000) 11:1531-1536.
24. FOSSELLA FV: Second-line chemotherapy for non-small-cell lung cancer. Curr. Oncol. Rep. (2000) 2(1):96-101.
25. UNTCH M, UNTCH A, SEVIN BU et al.: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs. (1994) 5(1):24-30.
26. VALERO V, JONES SE, VON HOFF DD et al.: A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. (1998) 16:3362-3368.
27. VERSCHRAEGEN CF, SITTISOMWONG T, KUDELKA AP et al.: Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J. Clin. Oncol. (2000) 18:2733-2739.
28. ROSE PG, BLESSING JA, BALL HG et al.: A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. (2003) 88:130-135.
29. DIERAS V, GUASTALLA JP, FERRERO JM et al.: A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study. Cancer Chemother. Pharmacol. (2004) 53:489-495.
30. PFISTERER J, DU BOIS A, WAGNER U et al.: Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol. Oncol. (2004) 92:949-956.
31. MARKMAN M, KENNEDY A, WEBSTER K et al.: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol. (2001) 19:1901-1905.
32. VASEY PA, JAYSON GC, GORDON A et al.: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Nat. Cancer Inst. (2004) 96(22):1682-1691.
33. ROTHENBERG ML: CPT-11: an original spectrum of clinical activity. Semin. Oncol. (1996) 23(Suppl. 3):21-6.
34. ROTHENBERG ML: Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. Oncologist (2001) 6:66-80.
35. KUNIMOTO T, NITTA K, TANAKA T et al.: Antitumor activity of 7-ethyl-10[4-(1- piperidino)]carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. (1987) 47:5944-5947.
36. ESCOBAR PF, MARKMAN M, ROSE P, ZANOTTI K, WEBSTER K, BELINSON J: Phase II trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol. Oncol. (2004) 92:192-196.
37. MAENPAA JU, HAGMAN E, KIVINEN S, POHTO M, KAAR K, JEKUNEN A: The combination of Taxoteres (T) and Camptos (C) for second line treatment of ovarian cancer - a Phase I dose-finding multicentre study (Abstr). Ann. Oncol. (1998) 9(Suppl. 4):334.
38. MAENPAA JU, KAAR K, KIVINEN S, POHTO M, JEKUNEN A: Docetaxel and CPT-11 for recurrent ovarian cancer - a Phase II study. Proc. Am. Soc. Clin. Oncol. (1999) 18:Abstr. 1403.
39. OULID-AISSA D, BRUNO R, LEBECQ A et al.: Taxotere safety in patients with impaired liver function (lf). Proc. ASCO (1996) 15:476a(1508a).
40. MARKMAN M, HOSKINS W: Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol. (1992) 10:513-514.
41. ROSE PG, SMREKAR M: Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. Gynecol. Oncol. (2003) 91:423-425.
42. RIGGS JE, ASHRAF M, SNYDER RD, GUTMANN L: Prospective nerve conduction studies in cisplatin therapy. Ann. Neurol. (1988) 23:92.
43. FAZIO R, QUATTRINI A, BOLOGNESI A et al.: Docetaxel neuropathy: a clinical and morphological study. J. Peripher. Nerv. Syst (1999) 4:69.
44. DELLON AL, SWIER P, MALONEY CT JR, LIVENGOOD MS, WERTER S: Chemotherapy-induced neuropathy: treatment by decompression of peripheral nerves. Plast. Reconstr. Surg. (2004) 114:478-483.
45. MOON C, VERSCHRAEGEN CF, BEVERS M et al.: Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs (2000) 11:565-568.
46. TERAUCHI F, HIRANO T, TACKA H et al.: Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Int. J. Clin. Oncol. (2003) 8:348-351.
47. BERKENBLIT A, SEIDEN MV, MATULONIS UA et al.: A Phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol. Oncol. (2004) 95(3):624-631.
48. ESMAELI B, VALERO V, AHMADI MA, BOOSER D: Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology (2001) 108:994-995.
49. MARKMAN M, LIU PY, WILCZYNSKI S et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecological Oncology Group trial. J. Clin. Oncol. (2003) 21(13):2460-2465.
50. PARMAR MK, LEDERMANN JA, COLOMBO N et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 361(9375):2099-2106.
51. GONZALEZ-MARTIN AA, CALVO E, BOVER I et al.: Randomized phase II study of carboplatin (C) versus paclitaxel-carboplatin (CP) in platinum-sensitive (PS) recurrent advanced ovarian carcinoma (AOC) with assessment of quality of life (QoL): A GEICO study (Spanish Group for Investigation on Ovarian Carcinoma). Proc. Am. Soc. Clin. Oncol. (2003):451 (Abstr. 1812).